Status:
UNKNOWN
Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children
Lead Sponsor:
Mansoura University
Conditions:
Voiding Disorders
Overactive Bladder
Eligibility:
All Genders
5-18 years
Phase:
PHASE1
PHASE2
Brief Summary
A randomized clinical study to evaluate the safety and efficacy of using the Beta 3 agonist drug (Mirabegron) combined with standard behavioral therapy in comparison to using the anticholinergic drug ...
Detailed Description
The study aims to evaluate the beta 3 agonist drug (Mirabegron) as regard its safety and efficacy when used in children with non neurogenic voiding dysfunction, including children suffering from frequ...
Eligibility Criteria
Inclusion
- Children with non-neurogenic voiding dysfunction predominantly filling phase dysfunctions or OAB, refractory to behavioral therapy as a primary monotherapy, with dysfunctional voiding symptom score of ≥6 for females and ≥9 for males, between the age of 5 \& 18 years old.
Exclusion
- Neurogenic or anatomical bladder problems.
- Patients with contraindications to Beta 3 agonists or anticholinergic drugs.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05240456
Start Date
February 1 2022
End Date
December 1 2022
Last Update
February 15 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.